Traders sold shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) on strength during trading hours on Friday. $8.51 million flowed into the stock on the tick-up and $31.23 million flowed out of the stock on the tick-down, for a money net flow of $22.72 million out of the stock. Of all stocks tracked, DENTSPLY SIRONA had the 0th highest net out-flow for the day. DENTSPLY SIRONA traded up $0.37 for the day and closed at $67.55

XRAY has been the subject of several research analyst reports. BidaskClub downgraded DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Zacks Investment Research cut DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a report on Monday, October 30th. Morgan Stanley restated an “overweight” rating and set a $69.00 price target (up from $67.00) on shares of DENTSPLY SIRONA in a report on Friday, October 6th. HC Wainwright restated a “buy” rating and set a $68.00 price target on shares of DENTSPLY SIRONA in a report on Monday, November 6th. Finally, Cleveland Research cut DENTSPLY SIRONA from a “buy” rating to a “neutral” rating in a report on Thursday, October 5th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. DENTSPLY SIRONA currently has an average rating of “Hold” and an average price target of $67.00.

The stock has a market cap of $15,515.09, a price-to-earnings ratio of 26.91, a price-to-earnings-growth ratio of 2.67 and a beta of 1.27. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.32 and a quick ratio of 1.59.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. During the same period in the prior year, the business posted $0.66 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. analysts expect that DENTSPLY SIRONA Inc. will post 2.66 earnings per share for the current fiscal year.

In related news, CFO Nicholas W. Alexos bought 50,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, November 13th. The shares were acquired at an average cost of $65.85 per share, for a total transaction of $3,292,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mark Thierer bought 77,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average price of $66.04 per share, for a total transaction of $5,085,080.00. The disclosure for this purchase can be found here. Corporate insiders own 1.99% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in DENTSPLY SIRONA by 2.5% in the second quarter. Vanguard Group Inc. now owns 22,728,062 shares of the medical instruments supplier’s stock valued at $1,473,688,000 after buying an additional 562,993 shares during the period. Ruane Cunniff & Goldfarb Inc. lifted its stake in DENTSPLY SIRONA by 0.5% in the third quarter. Ruane Cunniff & Goldfarb Inc. now owns 8,890,655 shares of the medical instruments supplier’s stock valued at $531,750,000 after buying an additional 40,767 shares during the period. Principal Financial Group Inc. lifted its stake in DENTSPLY SIRONA by 6.7% in the third quarter. Principal Financial Group Inc. now owns 6,910,770 shares of the medical instruments supplier’s stock valued at $413,333,000 after buying an additional 436,338 shares during the period. Jackson Square Partners LLC lifted its stake in DENTSPLY SIRONA by 15.6% in the third quarter. Jackson Square Partners LLC now owns 6,334,906 shares of the medical instruments supplier’s stock valued at $378,890,000 after buying an additional 855,199 shares during the period. Finally, Veritas Asset Management LLP lifted its stake in DENTSPLY SIRONA by 2.6% in the second quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock valued at $402,083,000 after buying an additional 157,616 shares during the period. Institutional investors and hedge funds own 94.65% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Traders Sell DENTSPLY SIRONA Inc. (XRAY) on Strength (XRAY)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/11/19/traders-sell-dentsply-sirona-inc-xray-on-strength-xray.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.